STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2484 by analyst upside · 2026-08-14
PODD
Insulet Corporation
Healthcare · Market Cap $10B · P/E 27.4x
ANALYST PRICE TARGET
+17.4%
implied upside to consensus target
Current Price $146.44
Consensus Target $171.91
Bull Target $275.0
Bear Target $144.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
10
Hold
9
Sell
0
52-Week Low $126.4
52-Week High $354.88
YTD Return -48.2%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 27.4x
Forward P/E 19.0x
EPS (TTM) $5.34
PEG Ratio 1.42
Dividend Yield N/A
Revenue (TTM) $3.1B
Profit Margin 12.3%
52-WEEK RANGE
52-Week Low $126.4
52-Week High $354.88
Current Price $146.44
Bear Target $144.0
Bull Target $275.0
● Now $146.44 ● Target $171.91
TRADING DATA
Avg Volume 1.6M
YTD Return -48.2%
Analyst Count 22
Consensus Buy
Upside to Target +17.4%
Last Updated 2026-08-14

ANALYST SUMMARY

Insulet Corporation (PODD) is currently trading at $146.44 with a Wall Street consensus price target of $171.91, implying potential upside of 17.4% over the next 12 months. 22 analysts currently cover PODD, with a consensus rating of Buy - 61% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $275.0, while the most cautious has a target of $144.0.

PODD operates in the Healthcare sector with a market capitalisation of $10B. The stock is down 48.2% year-to-date and is currently trading near the lower end of its 52-week range of $126.4 – $354.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PODD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Buy → Buy 2026-06-12 Building track record
Citigroup - Reiterated
Neutral → Neutral 2026-05-28 Building track record
RBC Capital reit
Outperform → Outperform 2026-05-27 Building track record
BTIG - Reiterated
Buy → Buy 2026-05-27 38% win rate (8 calls)
B of A Securities - Reiterated
Buy → Buy 2026-05-18 Building track record
Barclays - Reiterated
Underweight → Underweight 2026-05-08 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-05-07 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-05-07 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
24/30
Consensus clarity
12/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →